Rybrevant is a prescription medication used in cancer treatment, specifically targeting advanced or metastatic non-small cell lung cancer (NSCLC) with certain genetic mutations. It is a monoclonal antibody that works by targeting cancer cell growth pathways, offering a novel therapeutic option for eligible patients.

Rybrevant is a fully human EGFR-MET bispecific antibody. It works by:

1. Binding to EGFR (Epidermal Growth Factor Receptor) and MET (Mesenchymal-Epithelial Transition factor), two proteins that promote cancer cell growth and survival.
2. Blocking the signaling pathways that cancer cells use to grow and proliferate.
3. Inducing cancer cell death by engaging the immune system to attack cancer cells.